medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2019, Number 3

<< Back Next >>

Acta Med 2019; 17 (3)

Neuroleptic malignant syndrome

Ortega CMJ, Díaz GE, Rodríguez WF

Language: Spanish
References: 26
Page: 282-286
PDF size: 138.45 Kb.


ABSTRACT

Initially described in 1960 by Delay et al; it is a rare but potentially deadly. The presentation of hypothermia, alterations in consciousness levels, muscular rigidity and disautonomy are characteristic. It’s a secondary idiosyncratic response to the administration of neuroleptics, most frequently related with the administration of medications acting upon type 2 dopaminergic receptors. Treatment consists of discontinuing the drug, hemodynamic support and complication prevention. Mortality results from systemic complications and clinical manifestations. We present a case, a female patient with past medical history of major depressive disorder and generalized anxiety, she is admitted to the emergency room with clinical signs suggestive of malignant neuroleptic syndrome caused by intentional ingestion of multiple drugs; she is admitted to hospital for close monitorization.


REFERENCES

  1. Caroff SN, Mann SC, Campbell EC. Hipertermia y síndrome maligno ocasionado por neurolépticos. Anesth Clin North Am. 1994; 3: 523-543.

  2. Gelenberg AJ, Bellinghausen B, Wojcik JD, Falk WE, Sachs GS. A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry. 1988; 145 (4): 517-518.

  3. Hermesh H, Aizenberg D, Lapidot M, Munitz H. Risk of malignant hyperthermia among patients with neuroleptic malignant syndrome and their families. Am J Psychiatry. 1988; 145 (11): 1431-1434.

  4. Adityanjee, Aderibigbe YA, Mathews T. Epidemiology of neuroleptic malignant syndrome. Clin Neuropharmacol. 1999; 22 (3): 151-158.

  5. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985; 142 (10): 1137-1145.

  6. Nimmo SM, Kennedy BW, Tullett WM, Blyth AS, Dougall JR. Drug-induced hyperthermia. Anaesthesia. 1993; 48: 892-895.

  7. Velamoor VR. Neuroleptic malignant syndrome. Recognition, prevention and management. Drug Saf. 1998; 19 (1): 73-82.

  8. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993; 77 (1): 185-202.

  9. Keck PE Jr, Pope HG Jr, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry. 1989; 46 (10): 914-918.

  10. Chandran GJ, Mikler JR, Keegan DL. Neuroleptic malignant syndrome: case report and discussion. CMAJ. 2003; 169 (5): 439-442.

  11. Hayashi K, Chihara E, Sawa T, Tanaka Y. Clinical features of neuroleptic malignant syndrome in basal ganglia disease. Spontaneous presentation in a patient with Hallervorden-Spatz disease in the absence of neuroleptic drugs. Anaesthesia. 1993; 48 (6): 499-502.

  12. Rosenberg AD, Bernstein RL, Grande CM. Problems in anesthesia. Philadelphia: J.B. Lippincott Company; Volume 8. Number 3. 1994. pp. 148-156.

  13. Addonizio G, Susman V. Neuroleptic malignant syndrome and use of anesthetic agents. Am J Psychiatry. 1986; 143 (1): 127-128.

  14. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. 1999; 156 (2): 169-180.

  15. Ebadi M, Srinivasan SK. Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Pharmacol Rev. 1995; 47 (4): 575-604.

  16. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000; 85 (1): 129-135.

  17. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007; 164 (6): 870-876.

  18. Knorr R, Schöllkopf J, Haen E. Neuroleptic malignant syndrome. Nervenarzt. 2018; 89 (3): 300-310.

  19. Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist. 2011; 1 (1): 41-47.

  20. Tsujimoto S, Maeda K, Sugiyama T, Yokochi A, Chikusa H, Maruyama K. Efficacy of prolonged large-dose dantrolene for severe neuroleptic malignant syndrome. Anesth Analg. 1998; 86 (5): 1143-1144.

  21. Caroff SN, Mann SC, Keck PE Jr. Specific treatment of the neuroleptic malignant syndrome. Biol Psychiatry. 1998; 44 (6): 378-381.

  22. Gaitini L, Fradis M, Vaida S, Krimerman S, Beny A. Plasmapheresis in neuroleptic malignant syndrome. Anaesthesia. 1997; 52 (2): 165-168.

  23. Birmes P, Coppin D, Schmitt L, Lauque D. Serotonin syndrome: a brief review. CMAJ. 2003; 168 (11): 1439-1442.

  24. Ener RA, Meglathery SB, Van Decker WA, Gallagher RM. Serotonin syndrome and other serotonergic disorders. Pain Med. 2003; 4 (1): 63-74.

  25. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989; 50 (1): 18-25.

  26. Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic malignant syndrome: complications, outcomes, and mortality. Neurocrit Care. 2016; 24 (1): 97-103.




2020     |     www.medigraphic.com